Consolidating the evidence for correlates of protection for MARV, SUDV and EBOV
The traditional pathway to demonstrate vaccine efficacy via a randomised, placebo-controlled trial is not always possible. In these circumstances, different approaches and evidence need to be considered to determine effectiveness of vaccine candidates and to support licensure. Such evidence may include data from natural history, animal and in vitro studies, often involving analysis of immune responses and their association with protection.
Confirmation of a predictive biomarker or correlate of protection from such studies may significantly accelerate the development and approval of a vaccine.
Consolidation of the evidence is the first step in identifying whether there is sufficient evidence across multiple studies to identify a correlate of protection for pathogens.
This project aims to provide a consolidation and summary of the available evidence to support demonstration of effectiveness of developmental vaccines for protection against Ebola disease (EBOV), Sudan disease (SUDV) and Marburg disease (MARV).
Development of Evidence Maps
An Evidence (gap) Map is a systematic evidence curation tool that displays all the available evidence relevant to a specific research question or topic of interest as a matrix.
Evidence Maps provide a foundation for future, more focused evidence synthesis by identifying where substantial evidence exists and can also identify areas of need for further research (i.e. ‘gaps’).
View our MARV Map
This project is funded by:
The Filovirus project is a collaboration between the Kirby Institute and ALEC.
Contact us by emailing: [email protected]
